FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback - STAT
FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the selected dose
Search Group
Share To
Comments
About Screade
Screade® Inc. version be4f997, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments